Articles dans des revues avec comité de lecture (47)
  1. 1. Bodac, A., Mayet, A., Rana, S., Pascual, J., Bowler, A. D., Roh, V., Fournier, N., Craciun, L., Demetter, P., Radtke, F., & Meylan, E. (2024). Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth. EMBO molecular medicine, 16(1), 158-184. doi:10.1038/s44321-023-00013-x
  2. 2. Davenne, T., Percier, P., Larbanoix, L., Moser, M., Leo, O., Meylan, E., Goriely, S., Gérard, P., Wauthoz, N., Laurent, S., Amighi, K., & Rosiere, R. (2022). Inhaled dry powder cisplatin increases antitumour response to anti-PD1 in a murine lung cancer model. Journal of controlled release, 353, 317-326. doi:10.1016/j.jconrel.2022.11.055
  3. 3. Quail, D., Amulic, B., Aziz, M., Barnes, B., Eruslanov, E., Fridlender, Z., Goodridge, H., Granot, Z., Hidalgo, A., Huttenlocher, A., Kaplan, M. J., Malanchi, I., Merghoub, T., Meylan, E., Mittal, V., Pittet, M. J., Rubio-Ponce, A., Udalova, I., van den Berg, T. K., Wagner, D. D., Wang, P., Zychlinsky, A., de Visser, K. E., Egeblad, M., & Kubes, P. (2022). Neutrophil phenotypes and functions in cancer: A consensus statement. The Journal of experimental medicine, 219(6). doi:10.1084/jem.20220011
  4. 4. Pinjusic, K., Dubey, O. A., Egorova, O., Nassiri, S., Meylan, E., Faget, J., & Constam, D. B. (2022). Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma. Journal for ImmunoTherapy of Cancer, 10(5), e004533. doi:10.1136/jitc-2022-004533
  5. 5. Bodac, A., & Meylan, E. (2021). Neutrophil metabolism in the cancer context. Seminars in immunology., 101583. doi:10.1016/j.smim.2021.101583
  6. 6. Martinez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., Ries, C. H., Meylan, E., & De Palma, M. (2021). Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science Translational Medicine, 13(606). doi:10.1126/scitranslmed.abd1616
  7. 7. Faget, J., Peters, S., Quantin, X., Meylan, E., & Bonnefoy, N. (2021). Neutrophils in the era of immune checkpoint blockade. Journal for ImmunoTherapy of Cancer, 9(7), e002242. doi:10.1136/jitc-2020-002242
  8. 8. Ancey, P.-B., Contat, C., Boivin, G., Sabatino, S., Pascual, J., Zangger, N., Perentes, J. Y., Peters, S., Abel, D., Kirsch, D., Rathmell, J., Vozenin, M.-C., & Meylan, E. (2021). GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy. Cancer research, 81(9), 2345-2357. doi:10.1158/0008-5472.CAN-20-2870
  9. 9. Boivin, G., Ancey, P.-B., Vuillefroy de Silly, R., Kalambaden, P., Contat, C., Petit, B., Ollivier, J., Bourhis, J., Meylan, E., & Vozenin, M.-C. (2021). Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy. Oncoimmunology, 10(1). doi:10.1080/2162402X.2021.1876597
  10. 10. Boivin, G., Faget, J., Ancey, P.-B., Gkasti, A., Mussard, J., Engblom, C., Pfirschke, C., Contat, C., Pascual, J., Vazquez, J., Bendriss-Vermare, N., Caux, C., Vozenin, M.-C., Pittet, M., Gunzer, M., & Meylan, E. (2020). Durable and controlled depletion of neutrophils in mice. Nature communications, 11(1). doi:10.1038/s41467-020-16596-9
  11. 11. Cavin, S., Gkasti, A., Faget, J., Hao, Y., Letovanec, I., Reichenbach, M., Gonzalez, M., Krueger, T., Dyson, P., Meylan, E., & Perentes, J. Y. (2020). Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma. European journal of cardio-thoracic surgery, 58(4), 783-791. doi:10.1093/ejcts/ezaa145
  12. 12. Pfirschke, C., Engblom, C., Gungabeesoon, J., Lin, Y., Rickelt, S., Zilionis, R., Messemaker, M., Siwicki, M., Gerhard, G. M., Kohl, A., Meylan, E., Weissleder, R., Klein, A. M., & Pittet, M. (2020). Tumor-Promoting Ly-6G+ SiglecFhigh Cells Are Mature and Long-Lived Neutrophils. Cell reports, 32(12). doi:10.1016/j.celrep.2020.108164
    13. << Précédent 1 2 3 4 5 Suivant >>